Baricitinib and primary biliary cholangitis

BACKGROUND AND AIMS: There is an unmet need for alternative treatments for patients with primary biliary cholangitis (PBC) who do not respond to treatment with ursodeoxycholic acid (UDCA). A proof-of-concept study of baricitinib, an orally administered Janus kinase 1 and 2 inhibitor, was initiated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Stuart C., Trudeau, Sheri, Regev, Arie, Uhas, Jonathan M., Chakladar, Sujatro, Pinto-Correia, Ana, Gottlieb, Klaus, Schlichting, Doug
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240017/
https://www.ncbi.nlm.nih.gov/pubmed/34195587
http://dx.doi.org/10.1016/j.jtauto.2021.100107

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240017/
https://www.ncbi.nlm.nih.gov/pubmed/34195587
http://dx.doi.org/10.1016/j.jtauto.2021.100107

Ejemplares similares